HeartSciences (NASDAQ:HSCS) Releases Earnings Results, Misses Estimates By $0.14 EPS

Posted by Stacy Sanders on Sep 14th, 2026

HeartSciences (NASDAQ:HSCS – Get Free Report) released its earnings results on Monday. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.14), FiscalAI reports. The firm had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $0.10 million.

HeartSciences Trading Up 4.4%

Shares of NASDAQ HSCS traded up $0.15 during trading hours on Monday, reaching $3.54. The stock had a trading volume of 76,855 shares, compared to its average volume of 848,374. HeartSciences has a 52-week low of $1.63 and a 52-week high of $4.35. The firm has a market cap of $13.81 million, a price-to-earnings ratio of -0.90 and a beta of 1.85. The business’s fifty day moving average price is $2.67 and its two-hundred day moving average price is $2.38.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on HSCS shares. Wall Street Zen upgraded HeartSciences to a “sell” rating in a report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Read Our Latest Analysis on HSCS

HeartSciences Company Profile

(Get Free Report)

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.